4.7 Article

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia

Journal

LEUKEMIA
Volume 30, Issue 8, Pages 1672-1681

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2016.69

Keywords

-

Funding

  1. Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award
  2. NMRC Centre Grant
  3. National Research Foundation Singapore
  4. Singapore Ministry of Education under its Research Centers of Excellence initiative
  5. NIH/NCI [R01CA026038-35]
  6. NCI [CA31946]
  7. Deutsche Forschungsgemeinschaft [HE 5240/5-1]
  8. Senior Fellowship program of Wellcome DBT India Alliance, New Delhi, India [IA/S/11/2500267]
  9. Council for Scientific and Industrial Research (CSIR), New Delhi, India
  10. Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center through the Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy Project
  11. NCIS Centre Grant Seed Funding
  12. [OMRPG3C0021]
  13. [MOHW104-TDU-B-212-124-006]

Ask authors/readers for more resources

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15; 17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n = 12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo

Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.

BLOOD (2023)

Article Hematology

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Misha C. Tran, Yasmin Hasan, Amy Wang, Kamil Yenice, Julien Partouche, Wendy Stock, Richard A. Larson, Satyajit Kosuri, James L. LaBelle, Justin Kline, Peter A. Riedell, Andrew S. Artz, Ralph Weichselbaum, Michael R. Bishop, Bulent Aydogan, Hongtao Liu

Summary: Relapse after allo-SCT is a common issue, and a second SCT can be considered for treatment. The study explored the feasibility of combining IM-TMI with fludarabine and melphalan for conditioning in patients undergoing a second or greater allo-SCT. The results showed that the combination therapy was feasible and achieved favorable outcomes.

BLOOD ADVANCES (2023)

Article Hematology

Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms

Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel

Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial

Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah, Timothy P. Hughes

Summary: Asciminib, a BCR-ABL1 inhibitor that works through the STAMP mechanism, has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase. The ongoing ASC4FIRST trial aims to compare the effectiveness of Asciminib with investigator-selected TKIs in newly diagnosed patients with chronic myeloid leukemia.

FUTURE ONCOLOGY (2023)

Article Integrative & Complementary Medicine

Arsenicum album Induces Cell Cycle Arrest and Apoptosis, and Inhibits Epithelial-Mesenchymal Transition in Hormone-Dependent MCF7 Breast Cancer Cells

Nilanjana Basu, Manoj Garg, Chanderdeep Tandon, Bhudev Chandra Das, Simran Tandon

Summary: The study evaluated the anti-cancer potential of arsenic trioxide in hormone-dependent breast cancer. The results showed that arsenic trioxide could inhibit cell proliferation, induce apoptosis, and reduce cell migration in breast cancer cells. Further research is needed to elucidate the mechanism of action of arsenic trioxide in vivo.

HOMEOPATHY (2023)

Article Hematology

Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID-19 infection

Dorit Blickstein, Marina Izak, Talia Filipovich-Rimon, Osnat Garach-Jehoshua, Naomi Rahimi-Levene, Eilat Shinar, Ramzia Abu Hamad, Adina Bar-Chaim, Maya Koren-Michowitz

Summary: This study aimed to evaluate the prevalence of antiphospholipid antibodies (APLA) in convalescent plasma (CP) obtained from COVID-19 patients and assess the potential risk of thrombosis in transfused patients. The results showed that out of 122 CP samples, 7 samples (6%) tested positive for APLA. The low prevalence of APLA in CP donors reassured the safety of CP administration to patients with severe COVID-19.

VOX SANGUINIS (2023)

Article Chemistry, Multidisciplinary

Design and Synthesis of Thiazole Scaffold-Based Small Molecules as Anticancer Agents Targeting the Human Lactate Dehydrogenase A Enzyme

Dolly Sharma, Mamta Singh, Jayadev Joshi, Manoj Garg, Vidhi Chaudhary, Daniel Blankenberg, Sudhir Chandna, Vinit Kumar, Reshma Rani

Summary: A series of new thiazole-based small molecules were designed using a computer simulation approach and showed strong inhibition of hLDHA. Molecular docking analysis revealed specific amino acids that interacted strongly with the designed compounds. The synthesized compounds demonstrated good hLDHA inhibitory activity and anticancer activity in multiple cancer cell lines, with compounds 8b, 8c, and 8l showing the highest inhibitory activity. These compounds also exhibited significant anticancer activity in liver cancer cells without noticeable toxicity in human cells, indicating their potential as therapeutic agents. In silico profiling confirmed the drug-likeness of the compounds and suggested their suitability for further development.

ACS OMEGA (2023)

Article Biochemistry & Molecular Biology

Chemo-Enzymatic Fluorescence Labeling Of Genomic DNA For Simultaneous Detection Of Global 5-Methylcytosine And 5-Hydroxymethylcytosine

Sigal Avraham, Leonie Schuetz, Larissa Kaever, Andreas Dankers, Sapir Margalit, Yael Michaeli, Shahar Zirkin, Dmitry Torchinsky, Noa Gilat, Omer Bahr, Gil Nifker, Maya Koren-Michowitz, Elmar Weinhold, Yuval Ebenstein

Summary: The article presents a new high-throughput platform for multi-color epigenetic analysis, which allows simultaneous detection of methylation and demethylation signals. By utilizing an engineered methyltransferase enzyme and enzymatic glycosylation, the study achieves simultaneous measurement of 5-hydroxymethylcytosine and 5-methylcytosine. The findings demonstrate the potential of using a simple blood test for epigenetic evaluation in clinical samples, benefiting research and patient management.

CHEMBIOCHEM (2023)

Article Biochemistry & Molecular Biology

In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer

Sunil Kumar, Iqra Ali, Faheem Abbas, Anurag Rana, Sadanand Pandey, Manoj Garg, Deepak Kumar

Summary: In this study, a library of 1843 benzimidazole-1,2,3-triazole hybrids was screened to identify potential epidermal growth factor receptor (EGFR) inhibitors for lung cancer treatment. The identified compounds showed stable interactions with EGFR and exhibited favorable drug-likeness properties and low toxicity. This research provides important insights into the development of potent and selective EGFR inhibitors for lung cancer treatment.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

Article Oncology

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Naval G. Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N. Tanaka, Terrence J. Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman

Summary: Magrolimab combined with azacitidine showed promising efficacy and tolerability in patients with untreated AML ineligible for intensive chemotherapy, including those with TP53 mutations.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer

Samarth Kansara, Agrata Singh, Abhishesh Kumar Badal, Reshma Rani, Prakash Baligar, Manoj Garg, Amit Kumar Pandey

Summary: Altered energy metabolism is a key characteristic of tumorigenesis, and non-coding RNAs (ncRNAs) play a significant role in regulating glucose metabolism in human cancers. In this review, the aberrant expression of glucose metabolic pathways in breast cancer is outlined, and the potential applications of ncRNAs in regulating energy pathways, as well as their importance in prognosis, diagnosis, and future therapeutics for breast carcinoma, are discussed.

SEMINARS IN CANCER BIOLOGY (2023)

Article Hematology

A Hematopoietic Stem Cell Transplantation Startup in Iraqi Kurdistan: Results in Thalassemia Patients and Analysis of the Methodology

Marta Verna, Marta Canesi, Valentino Conter, Lawrence Faulkner, Attilio Maria Rovelli, Daniela Silvestri, Ignazio Majolino, Andrea Biondi, Chra Nawfal Abdullah, Vian Faeq Mohammed

Summary: Thalassemia is a common and life-threatening disorder in children in regions prone to hemoglobinopathy, such as the Middle East. Hematopoietic stem cell transplantation (HSCT) is a highly effective and cost-effective treatment for thalassemia. A study in Iraqi Kurdistan demonstrated the successful establishment of an HSCT unit for both adults and children, achieving comparable results to international standards. The success of the program relied on meeting minimum requirements, international collaboration, and capacity-building efforts.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, GaryJ. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Yoshinobu Maeda, Naoko Hosono, Masahiro Onozawa, Takayasu Kato, Hee-Je Kim, Nahla Hasabou, Rishita Nuthethi, Ramon Tiu, Mark J. Levis

Summary: The ADMIRAL trial investigated the efficacy of using the FLT3 inhibitor gilteritinib as maintenance therapy after hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory FLT3-mutated AML. The results showed that gilteritinib maintenance therapy improved survival rates and was well-tolerated in patients post-HSCT.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases

Alessandro Cattoni, Giulia Capitoli, Sara Casagranda, Paola Corti, Marta Adavastro, Alessandro Molinaro, Filiberto Di Gennaro, Sonia Bonanomi, Andrea Biondi, Stefania Galimberti, Adriana Balduzzi

Summary: This retrospective study aimed to assess the prevalence, severity, risk factors, and management of iron overload (IOL) in pediatric patients who underwent hematopoietic stem cell transplantation (HSCT). The results showed that 73% of patients had some degree of IOL, with a higher severity observed in patients with malignant diseases. Pre-HSCT and maximum post-HSCT ferritin levels were statistically higher in patients with malignancies, and radiologic assessment confirmed a more severe degree of IOL in these patients.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Medicine, General & Internal

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srdan Verstovsek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung -Soo Yoon, Vikas Gupta, Jean -Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Barbara J. Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa

Summary: This study aimed to compare the clinical effects of momelotinib and danazol in patients with intermediate or high-risk myelofibrosis. The results showed that momelotinib can significantly improve myelofibrosis-associated symptoms, anemia measures, and spleen response compared to danazol, with favorable safety.

LANCET (2023)

No Data Available